Traditionally, in most common cancers, including breast cancer (BC), clinicopathological features (e.g., tumor size, lymph node status, TNM stage, histological grade, hormone receptor status, human epidermal growth factor receptor 2 [HER-2] amplification) are used to predict patient outcome [1]. This evidence concerns the gene ERBB2 and breast cancer.